Many older vaccines are already approved for this coming flu season, while many others remain in development. Some have been promised to the public despite complete lack of human trials of the COVID Omicron BA. 4 and BA. 5 variants.
It is amusing to watch the media, citing CDC, try to push as many vaccines as possible while admitting in the same article the vaccines don't actually work: if you are lucky to get some immunity from them, it quickly evaporates, while you are likely to get no immunity to current strains from the current vaccine, which is still based on the original Wuhan strain of COVID that disappeared 2 years ago.
For example, the NY Times bobs and weaves around these facts in a classic demonstration of propaganda, telling the truth but then immediately misdirecting your attention:
Some people may also be discouraged by new research that shows immunity against infection dips significantly within three months, and the newest Omicron subvariants are much more adept at dodging immunity than earlier versions of the virus, Dr. Osterholm added.
New vaccines more targeted toward Omicron subvariants will likely arrive in the fall, and the Biden administration is considering expanding booster eligibility. But if you are in a high-risk group that is eligible for second boosters, you should not try to game out the timing of your shots. According to the C.D.C., getting vaccinated now “will not prevent you from getting an authorized variant-specific vaccine in the fall or winter when they are recommended for you.”
NanoFlu is
a quadrivalent recombinant hemagglutinin (H.A.) protein nanoparticle
influenza vaccine produced by Novavax in its SF9 insect cell baculovirus
system. NanoFlu uses H.A. amino acid protein sequences similar to the
recommended wild-type circulating virus H.A. sequences. In addition,
NanoFlu contains Novavax's patented saponin-based Matrix-M™ adjuvant. [Note: the vaccine does not include neuraminidase antigens for influenza--Nass]
CureVac's seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, was developed with GSK. The differentiated multivalent vaccine candidate features multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains.
Moderna's combination respiratory vaccine candidate (mRNA-1230) is envisioned as an annual booster targeting SARS-CoV-2, influenza virus, and RSV vaccines.
Moderna's seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030, include eight mRNAs targeting hemagglutinin and neuraminidase at different doses and ratios.
Moderna's mRNA-1010 Quadrivalent Influenza Vaccine candidate encodes for the hemagglutinin protein from four seasonal influenza viruses, including A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. [Neuraminidase antigens have been omitted here too.--Nass]
Oh, and by the way, the precision vaccination site reveals that it may actually help you to get COVID and influenza at the same time. Look at this:
A peer-reviewed study
published by the Journal of Virology on Jul. 12, 2022, suggests
that coinfection with influenza A virus (IAV) and the SARS-CoV-2
coronavirus changes neither the trajectory nor the severity of influenza
A virus, regardless of timing. However, contracting influenza A first
could suppress any COVID-19 infection caused by SARS-CoV-2. 'We observe
a significant loss of SARS-CoV-2 replication following IAV
infection.' Notably, the investigators found that the influenza A virus
interferes with SARS-CoV-2 replication in the lung and can continue to
do so even more than one week after clearance of the IAV, according to
the research.
COVID-19 leaked from US biolab, claims Lancet's commission head; 'Not a natural spillover'
ReplyDeleteCoronavirus did not originate in the nature or animal, Sachs purported, negating the results from the WHO-China Joint Mission on Coronavirus Disease.
Zaini Majeed 2nd July, 2022
https://www.republicworld.com/world-news/us-news/covid-19-leaked-from-us-biolab-claims-lancets-commission-head-not-a-natural-spillover-articleshow.html
ReplyDeletehttps://www.sott.net/article/470580-Data-doesnt-lie-mRNA-vaccines-and-correlation-to-all-cause-mortality
People that have been vaccinated twice with the original vaccine, that at this moment there is zero protection anymore. So that's official result, that on the efficacy side (zero protection).
And the sad thing is that, although these people obeyed the rules of the government and trusted them, now that they have these terrible side effects, the government doesn't want to listen. You know, they are just so neglected. We don't talk about it. And that's the situation at the moment.
Most of the people are vaccinated in the Netherlands. It's something like 75%. So you cannot freak them out by saying you have something in your body that's going to be the end of your life, because that's what I'm trying to say
Dr. Theo Schetters: So it potentially affects all organs. And that's what the medical doctors now see, they see all sorts of symptoms that they do not know what it is. And because the adverse effects are so not just single one adverse effect, but can be anything, they surface very difficult to a statistical level. And that's why we do analysis on all cause mortality, because say, okay, and if we do not know what is exactly related to vaccination, of course, the coagulation problems, myocarditis, we know that, but there are many more things happening at the moment. And so that's why we look at all cause mortality, and in the Netherlands now it's very clear that there is a good correlation between the number of vaccinations that are given to people and the number of people that die within a week after that. So let's say in this week we gave 10,000 vaccinations. Then in this week, we have something like 125 excess in death in that week (My note - that equals 800 deaths per 100,000 or 1/800 in the 60+ cohort).
Marlies Dekkers: So if you have more vaccines in that week, then you also have more excess death.
Dr. Theo Schetters: Exactly. Yes.
Marlies Dekkers: If you have less vaccines in that week, you have less...
Dr. Theo Schetters: Fewer deaths.
Marlies Dekkers: I got goosebumps.
Dr. Theo Schetters: Yeah. And the point is, of course, we do not get the real, what we call the granular data, which means that we do not have this from person by person. These are group type figures. So that group received that number of vaccines. And in that age group, you see this number of excess mortality. But we do not know whether this is really correlated one by one. And so that's why we asked for more data, because Ronald Meza said - Ronald Meza is a professor in statistics and we've discussed it here and said, okay, give us those data within a week.
Dr. Theo Schetters: Yeah. Well, and that's the problem with this technology because this mRNA travels through your body because of the formulations that they used.
Dr. Robert Malo...: Which physicians were told was not the case.
So if you have more vaccines in that week, then you also have more excess death.
Dr. Theo Schetters: Exactly. Yes.
Marlies Dekkers: If you have less vaccines in that week, you have less...
Dr. Robert Malone: So all-cause mortality is the ultimate indicator for things that we didn't expect. And that's why we always have to have it in clinical research. And yet once again, like so many other things, we have disregarded the learning of decades and denied the importance of all-cause mortality.
Dr. Theo Schetters: Yeah. So what we've done is we have written a registered letter to the director of our Institute of Health and presenting the results and expressing my concerns. And just with the question, from a precautionary point of view, please reconsider vaccination strategy because I think this is a real warning.
Bats, Gene Editing and Bioweapons: Recent DARPA Experiments Raise Concerns Amid Coronavirus Outbreak - Europe Reloaded
ReplyDeletehttps://www.europereloaded.com/bats-gene-editing-and-bioweapons-recent-darpa-experiments-raise-concerns-amid-coronavirus-outbreak/
Bat SARS-like coronavirus WIV1 encodes an extra accessory protein ORFX involved in modulation of host immune response | Request PDF
https://www.researchgate.net/publication/302972236_Bat_SARS-like_coronavirus_WIV1_encodes_an_extra_accessory_protein_ORFX_involved_in_modulation_of_host_immune_response